Aiming at Neuroblastoma and Hitting Other Worthy Targets

1 Departments of Pediatrics, Neurology, and Neurobiology & Anatomy, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Journal of child neurology (Impact Factor: 1.72). 04/2013; 28(6). DOI: 10.1177/0883073813483173
Source: PubMed


Neuroblastoma is, at once, the most common and deadly extracranial solid tumor of childhood. Efforts aimed at targeting the neural characteristics of these tumors have taught us much about neural crest cell biology, apoptosis induction in the nervous system, and neurotrophin receptor signaling and intracellular processing. But neuroblastoma remains a formidable enemy to the oncologist and an enigmatic target to the neuroscientist.

Download full-text


Available from: Nina F Schor, Oct 05, 2015
13 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: While neuroscientists are often involved in the assessment and care of patients with central nervous system tumors, they are only rarely involved in the case of peripheral nervous system neoplasia. Neuroblastoma is a childhood tumor of the primitive sympathetic nervous system. It is at once one of the most common and one of the most deadly tumors of childhood. The prognosis for children with this tumor has not changed in the past two decades. Clearly, a fresh approach to neuroblastoma is needed. The neuroscientist has much to add to our understanding and treatment of neuroblastoma and its sequelae. Conversely, neuroblastoma has much to teach us regarding the normal development of the neural crest and the aberrant loss of neurons in this lineage. A neuroscientist's approach to neuroblastoma, its biology and clinical features, is presented herein.
    Journal of Neuro-Oncology 02/1999; 41(2):159-66. DOI:10.1023/A:1006171406740 · 3.07 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The neurotransmitter analogue 6-hydroxydopamine has been proposed as a selective chemotherapeutic agent for peripheral neural crest tumors. It exerts its action through the generation of cytotoxic oxygen free radicals. Unfortunately, it is toxic to normal peripheral neurons as well. Ethiofos (WR-2721) is a free radical scavenger which appears to be preferentially taken up by normal cells relative to some tumor cells. WR-2721 has been assayed as a protector of the normal autonomic nervous system in mice treated with 6-hydroxydopamine. Although WR-2721 has some activity in this regard, its therapeutic window is narrowed by its depletion of glutathione, a phenomenon which has not previously been noted with this drug. These findings raise issues regarding the safety of adjunctive use of WR-2721 with oxygen free radical-generating chemotherapeutic agents.
    Cancer Research 11/1987; 47(20):5411-4. · 9.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The radioprotective drug, WR-2721 (S,2-[3-aminopropylamino]ethyl-phosphorothioic acid), has been studied in terms of its ability to (a) protect mice against mechlorethamine (HN2)-induced hematopoietic death, and (b) alter the ability of HN2 injections to induce growth delay in a solid tumor, the Line 1 lung carcinoma. When WR-2721 was injected ip 15 minutes before iv injections of HN2, it increased resistance to hematopoietic death by a factor of 2, and the protection declined with a half-life of 1.5-2.0 hours. Similar administration of both drugs failed to alter the responsiveness of the Line 1 lung carcinoma to HN2-induced growth delays, except when the HN2 was given within 15 minutes after WR-2721. This interaction of the two drugs, when given within 5-15 minutes of each other, does not appear to be true protection at the tumor site, but rather appears to result from HN2 inactivation in the blood. When HN2 is given 30-60 minutes after WR-2721, it is possible to obtain a twofold increase in the tumor delay without risking increased hematopoietic injury.
    Cancer treatment reports 07/1979; 63(6):971-6.
Show more